Holen Sie sich die Stockscreener-App
12.35
0.57%
0.07
Handel nachbörslich:
12.35
Schlusskurs vom Vortag:
$12.28
Offen:
$12.28
24-Stunden-Volumen:
377.34K
Relative Volume:
0.87
Marktkapitalisierung:
$349.86M
Einnahmen:
$157.75M
Nettoeinkommen (Verlust:
$-29.73M
KGV:
-10.65
EPS:
-1.16
Netto-Cashflow:
$-21.00M
1W Leistung:
-0.72%
1M Leistung:
+6.01%
6M Leistung:
-16.67%
1J Leistung:
-52.43%
1-Tages-Spanne:
$12.10
$12.98
1-Wochen-Bereich:
$12.01
$13.42
52-Wochen-Spanne:
$8.04
$28.05
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Firmenname
Arcturus Therapeutics Holdings Inc
Sektor
Branche
Telefon
(858) 900-2660
Adresse
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Vergleichen Sie ARCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
12.35 | 349.86M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.58 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-28 | Eingeleitet | BTIG Research | Buy |
| 2024-08-12 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-07-24 | Eingeleitet | William Blair | Outperform |
| 2023-05-11 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-11-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-11-02 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-01-31 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Herabstufung | Goldman | Neutral → Sell |
| 2021-08-10 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Fortgesetzt | Goldman | Neutral |
| 2021-06-21 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-17 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Eingeleitet | Wells Fargo | Overweight |
| 2020-12-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Herabstufung | ROTH Capital | Buy → Sell |
| 2020-12-08 | Bestätigt | B. Riley Securities | Buy |
| 2020-12-07 | Bestätigt | B. Riley Securities | Buy |
| 2020-10-26 | Eingeleitet | Barclays | Overweight |
| 2020-10-06 | Eingeleitet | Citigroup | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-30 | Fortgesetzt | ROTH Capital | Buy |
| 2020-07-16 | Eingeleitet | Raymond James | Outperform |
| 2020-07-13 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-09 | Herabstufung | WBB Securities | Buy → Hold |
| 2020-02-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-07 | Eingeleitet | Guggenheim | Buy |
| 2020-02-06 | Eingeleitet | Guggenheim | Buy |
| 2019-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-09-20 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by Bank of America Corp DE - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Analysts Offer Predictions for ARCT FY2026 Earnings - Defense World
Two Sigma Investments LP Increases Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
(ARCT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Squarepoint Ops LLC Sells 22,752 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings Inc (ARCT) Is A Good Stock To Invest In - Stocksregister
Arcturus Therapeutics Approves Key Proposals at Annual Meeting - TipRanks
Transcript : Arcturus Therapeutics Holdings Inc.Shareholder/Analyst Call - marketscreener.com
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Position Increased by Ameriprise Financial Inc. - Defense World
Nuveen Asset Management LLC Sells 10,221 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
BNP Paribas Financial Markets Sells 13,093 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet - sharewise
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Purchased by Deutsche Bank AG - Defense World
Arcturus Therapeutics to Attend Upcoming Investor Conferences - Business Wire
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at Scotiabank - Defense World
Scotiabank Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Sector Outperform Recommendation - Nasdaq
When the Price of (ARCT) Talks, People Listen - news.stocktradersdaily.com
Scotiabank Initiates Coverage on Arcturus Therapeutics (ARCT) | - GuruFocus
Arcturus Therapeutics (ARCT) Receives Positive Outlook with Potential Upside | ARCT Stock News - GuruFocus
Scotiabank Initiates Arcturus Therapeutics at Outperform - marketscreener.com
Man Group plc Sells 4,168 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics’ SWOT analysis: mRNA innovator’s stock faces pivotal year - Investing.com India
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wall Street Zen Upgrades Arcturus Therapeutics (NASDAQ:ARCT) to “Hold” - Defense World
Arcturus Therapeutics Holdings (ARCT) Stock Analysis: A 481% Upside Potential Amidst Biotech Innovations - DirectorsTalk Interviews
Northern Trust Corp Has $4.35 Million Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Trend Tracker for (ARCT) - news.stocktradersdaily.com
Wells Fargo & Company Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $45.00 - Defense World
Arcturus signals extended cash runway into 2028 with strategic shift toward CF and OTC mRNA therapeutics - MSN
FY2025 EPS Estimates for ARCT Raised by Cantor Fitzgerald - The AM Reporter
Leerink Partnrs Analysts Raise Earnings Estimates for ARCT - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
William Blair Brokers Boost Earnings Estimates for ARCT - Defense World
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade - Yahoo Finance
Canaccord Genuity Group Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - Defense World
Arcturus Therapeutics (ARCT): Wells Fargo Maintains Rating, Lowe - GuruFocus
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Adjusts Price Target for Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Arcturus Therapeutics (ARCT) Set for Potential Upside with Citi's Confidence | ARCT Stock News - GuruFocus
Arcturus Therapeutics Holdings Inc earnings missed by $4.11, revenue fell short of estimates - Investing.com Nigeria
Canaccord Genuity Maintains Buy Rating on Arcturus Therapeutics (ARCT) | ARCT Stock News - GuruFocus
Demystifying Arcturus Therapeutics: Insights From 7 Analyst Reviews - Benzinga
Arcturus Therapeutics (ARCT) Price Target Revised by Canaccord | - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings: EPS - GuruFocus
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call Highlights: Strategic Focus and ... - Yahoo Finance
Arcturus Therapeutics stock jumps 7% despite Q1 loss By Investing.com - Investing.com India
Arcturus Therapeutics Holdings Inc (ARCT) Q1 2025 Earnings Call - GuruFocus
Arcturus Therapeutics Reports Q1 2025 Financial Update - TipRanks
Arcturus Therapeutics (ARCT) Sees Strong Progress with Pipeline Programs - GuruFocus
Earnings call transcript: Arcturus Therapeutics Q1 2025 sees revenue drop, stock rises - Investing.com
Finanzdaten der Arcturus Therapeutics Holdings Inc-Aktie (ARCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.13%
1.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):